Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Harvard Bioscience Q3 2026 Results: Net Loss of $2.62M, Loss Widens

Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue22.220.6
Gross profit12.312.0
Profit before tax-2.7-1.1
Net income-2.6-1.2
EPS (diluted, $ a share)$-0.58$-0.28

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+7.8%
Gross margin55.4%
Operating margin-5.2%
Source

10-Q filed with the SEC, NASDAQ: HBIO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Harvard Bioscience Inc: key numbers

Share price
$8.91Close, Nov 16
Market cap
$40.7M
Shares outstanding
4.57MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Harvard Bioscience Inc

All →
7:01 AM ET 8-K
Investor Presentation

Harvard Bioscience Investor Presentation

Harvard Bioscience filed its updated corporate slide presentation for November 2026 to provide the investment community with updates and summaries of its business operations. The presentation includes forward-looking information regarding expected financial performance, including adjusted EBITDA margins and the introduction of new products aimed at accelerating drug development.

7:00 AM ET 8-K
Financial Results

Harvard Bioscience Financial Results

Harvard Bioscience reported Q3 2026 revenue of $22.2 million, an 8% increase year-over-year, driven by strong demand from CROs and customers in China. The company reported a net loss of $2.6 million for the quarter and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%.

Term
Q3 2026

“We delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter. We saw solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products.”

John Duke, President and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.